INS and metabolic dysfunction-associated steatotic liver disease: PTP1B came into limelight as a primary target responsible for the progression of abnormal conditions like obesity, insulin resistance, and NAFLD, which is a down-regulator of leptin and insulin pathways (Delibegovic et al., 2009).